486 related articles for article (PubMed ID: 36960868)
1. Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review).
Zhang X; Wang Z; Zheng Y; Yu Q; Zeng M; Bai L; Yang L; Guo M; Jiang X; Gan J
Int J Mol Med; 2023 Apr; 51(4):. PubMed ID: 36960868
[TBL] [Abstract][Full Text] [Related]
2. The zebrafish NLRP3 inflammasome has functional roles in ASC-dependent interleukin-1β maturation and gasdermin E-mediated pyroptosis.
Li JY; Wang YY; Shao T; Fan DD; Lin AF; Xiang LX; Shao JZ
J Biol Chem; 2020 Jan; 295(4):1120-1141. PubMed ID: 31852739
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Inhibitors of the NLRP3 Inflammasome.
Zahid A; Li B; Kombe AJK; Jin T; Tao J
Front Immunol; 2019; 10():2538. PubMed ID: 31749805
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases.
Jahan S; Kumar D; Chaturvedi S; Rashid M; Wahajuddin M; Khan YA; Goyal SN; Patil CR; Mohanraj R; Subramanya S; Ojha S
Curr Med Chem; 2017; 24(16):1645-1670. PubMed ID: 28245768
[TBL] [Abstract][Full Text] [Related]
5. The NLRP3 inflammasome: contributions to inflammation-related diseases.
Chen Y; Ye X; Escames G; Lei W; Zhang X; Li M; Jing T; Yao Y; Qiu Z; Wang Z; Acuña-Castroviejo D; Yang Y
Cell Mol Biol Lett; 2023 Jun; 28(1):51. PubMed ID: 37370025
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases.
Seok JK; Kang HC; Cho YY; Lee HS; Lee JY
Arch Pharm Res; 2021 Jan; 44(1):16-35. PubMed ID: 33534121
[TBL] [Abstract][Full Text] [Related]
7. A novel cysteine protease inhibitor in Baylisascaris schroederi migratory larvae regulates inflammasome activation through the TLR4-ROS-NLRP3 pathway.
Xu J; Gu X; Xie Y; He R; Xu J; Xiong L; Peng X; Yang G
Parasit Vectors; 2022 Sep; 15(1):334. PubMed ID: 36151570
[TBL] [Abstract][Full Text] [Related]
8. Activation and Regulation of NLRP3 by Sterile and Infectious Insults.
Banerjee SK; Chatterjee A; Gupta S; Nagar A
Front Immunol; 2022; 13():896353. PubMed ID: 35663964
[TBL] [Abstract][Full Text] [Related]
9. NLRP3 inflammasome in ischemic stroke: As possible therapeutic target.
Alishahi M; Farzaneh M; Ghaedrahmati F; Nejabatdoust A; Sarkaki A; Khoshnam SE
Int J Stroke; 2019 Aug; 14(6):574-591. PubMed ID: 30940045
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors.
Zhan X; Li Q; Xu G; Xiao X; Bai Z
Front Immunol; 2022; 13():1109938. PubMed ID: 36741414
[TBL] [Abstract][Full Text] [Related]
11. A small molecule inhibitor of caspase-1 inhibits NLRP3 inflammasome activation and pyroptosis to alleviate gouty inflammation.
Cao DY; Zhang ZH; Li RZ; Shi XK; Xi RY; Zhang GL; Li F; Wang F
Immunol Lett; 2022 Apr; 244():28-39. PubMed ID: 35288207
[TBL] [Abstract][Full Text] [Related]
12. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.
Zhang X; Xu A; Lv J; Zhang Q; Ran Y; Wei C; Wu J
Eur J Med Chem; 2020 Jan; 185():111822. PubMed ID: 31699536
[TBL] [Abstract][Full Text] [Related]
13. Spirodalesol analog 8A inhibits NLRP3 inflammasome activation and attenuates inflammatory disease by directly targeting adaptor protein ASC.
Liu W; Yang J; Fang S; Jiao C; Gao J; Zhang A; Wu T; Tan R; Xu Q; Guo W
J Biol Chem; 2022 Dec; 298(12):102696. PubMed ID: 36379253
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of NLRP3 inflammasome by designed peptide originating from ASC.
Sušjan P; Lainšček D; Strmšek Ž; Hodnik V; Anderluh G; Hafner-Bratkovič I
FASEB J; 2020 Aug; 34(8):11068-11086. PubMed ID: 32648626
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors.
Zhao N; Li CC; Di B; Xu LL
J Autoimmun; 2020 Sep; 113():102515. PubMed ID: 32703754
[TBL] [Abstract][Full Text] [Related]
16. Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.
Rahman MM; McFadden G
J Virol; 2011 Dec; 85(23):12505-17. PubMed ID: 21957307
[TBL] [Abstract][Full Text] [Related]
17. Targeting the NLRP3 inflammasome in diabetic retinopathy: From pathogenesis to therapeutic strategies.
Yang Y; Jiang G; Huang R; Liu Y; Chang X; Fu S
Biochem Pharmacol; 2023 Jun; 212():115569. PubMed ID: 37100255
[TBL] [Abstract][Full Text] [Related]
18. The role of mitochondria in NLRP3 inflammasome activation.
Liu Q; Zhang D; Hu D; Zhou X; Zhou Y
Mol Immunol; 2018 Nov; 103():115-124. PubMed ID: 30248487
[TBL] [Abstract][Full Text] [Related]
19. Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis.
Wang Y; Fang D; Yang Q; You J; Wang L; Wu J; Zeng M; Luo M
Front Immunol; 2023; 14():1126823. PubMed ID: 36911736
[TBL] [Abstract][Full Text] [Related]
20. Sendai Virus V Protein Inhibits the Secretion of Interleukin-1β by Preventing NLRP3 Inflammasome Assembly.
Komatsu T; Tanaka Y; Kitagawa Y; Koide N; Naiki Y; Morita N; Gotoh B; Yokochi T
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
